Adderall XR Standard Titration Schedule

What Is the FDA-Approved Starting Dose for Adderall XR?

The FDA label for Adderall XR specifies a starting dose of 10 mg once daily in the morning for adults and adolescents aged 13 and older, and 5 mg once daily for children aged 6 to 12. These starting points reflect the lowest doses associated with meaningful efficacy in placebo-controlled trials while keeping early side effects manageable. Clinicians occasionally start adults at 5 mg if they have anxiety, low body weight, or prior sensitivity to stimulants.

Adult Starting Doses

For adults newly initiating mixed amphetamine salts extended-release, 10 mg each morning is standard. The FDA prescribing information for Adderall XR states that doses above 30 mg per day have not been studied in adults and are not recommended. Starting above 10 mg does not improve the speed of clinical response and increases early dropout due to insomnia and appetite loss.

Pediatric Starting Doses

Children aged 6 to 12 begin at 5 mg once daily per the FDA label. A single 5 mg capsule can be opened and sprinkled on applesauce for children who cannot swallow capsules, which the label explicitly permits. Children younger than 6 are not FDA-approved candidates for Adderall XR.

Adolescent Dosing

Adolescents aged 13 to 17 follow the adult 10 mg starting dose. In a randomized controlled trial of 287 adolescents published in the Journal of Child and Adolescent Psychopharmacology, doses from 10 mg to 30 mg were all significantly more effective than placebo on the ADHD-RS-IV total score, with effect sizes ranging from 0.6 to 1.0.

How Fast Can You Increase Adderall XR?

The FDA label permits dose escalation at weekly intervals. One week at each dose level gives the patient and clinician enough time to observe both therapeutic response and side effects at steady-state plasma concentrations. Rushing titration faster than weekly increments raises the risk of cardiovascular side effects and rebound dysphoria without improving the probability of landing on a correct maintenance dose sooner.

Weekly Escalation Steps

Each increase should be 5 mg or 10 mg. A 5 mg step is appropriate for patients reporting early side effects such as appetite loss of more than one meal per day, resting heart rate above 100 bpm, or new or worsened anxiety symptoms. A 10 mg step is reasonable when the prior dose produced no therapeutic response and no notable side effects. The FDA label does not endorse steps larger than 10 mg.

What the MTA Study Showed About Titration Speed

The Multimodal Treatment Study of Children with ADHD (MTA, N=579) used a structured titration algorithm beginning at 5 mg twice daily of immediate-release amphetamine salts, doubling weekly over three weeks to reach a maximum of 35 mg per day. Published in Archives of General Psychiatry (1999), the MTA study found that 75% of children in the medication arm achieved adequate symptom control by week 14, with a mean final dose of approximately 30 mg per day. The MTA protocol demonstrates that systematic, weekly dose escalation produces high response rates when clinicians assess outcomes at each step rather than escalating on a fixed schedule regardless of response.

Minimum Duration Before Increasing

At each dose level, allow at least 5 to 7 days before concluding the dose is insufficient. Adderall XR reaches steady-state plasma concentrations within two to four days of a consistent daily dose per pharmacokinetic data reviewed by the FDA, so by day 5 or 6 the patient is experiencing representative drug exposure. Dose increases made before day 5 risk overshooting the target dose.

What Is the Target Therapeutic Dose Range?

Most adults achieve meaningful ADHD symptom reduction at 10 mg to 20 mg per day. The ceiling of 30 mg per day represents the highest dose tested in key adult trials. Some patients require 20 mg to 30 mg; a minority of patients find 10 mg sufficient.

Evidence From Controlled Adult Trials

A double-blind, placebo-controlled trial of 255 adults with ADHD published in Biological Psychiatry (2005) found that Adderall XR 20 mg and 30 mg both produced statistically significant reductions in ADHD-RS total scores compared to placebo (P<0.001), while 10 mg produced a trend that did not reach significance in that sample. Responder rates at 20 mg and 30 mg were 56% and 65%, respectively, versus 22% for placebo.

Pediatric Target Doses

In children aged 6 to 12, most clinical benefit accrues between 10 mg and 25 mg per day. The AHRQ Comparative Effectiveness Review on ADHD Medications noted that pediatric dose-response relationships for amphetamine formulations are approximately linear up to 20 mg, with diminishing marginal returns above that threshold for many children.

Why the 30 mg Label Ceiling Exists

Adderall XR trials submitted to the FDA did not include doses above 30 mg in adults or 30 mg in children. The FDA label explicitly states: "Doses greater than 30 mg/day of Adderall XR have not been studied in children." Prescribing above that ceiling is off-label and requires documented clinical justification in the medical record.

How Do Clinicians Assess Response at Each Dose Level?

Dose escalation decisions should be based on structured symptom ratings rather than patient report alone. Validated tools include the ADHD Rating Scale IV (ADHD-RS-IV), the Conners Rating Scales (3rd edition), and the Adult ADHD Self-Report Scale (ASRS v1.1). A clinician should also check blood pressure and heart rate at each titration visit.

Using the ADHD-RS-IV as a Titration Anchor

The ADHD-RS-IV has 18 items scored 0 to 3, giving a maximum total score of 54. A reduction of 30% or more from baseline is the standard threshold for "response" used in most key trials, including the adolescent Adderall XR trial cited above. If a patient achieves less than 20% reduction at a given dose after 7 days, escalation is appropriate provided vital signs are acceptable.

Cardiovascular Monitoring During Titration

The FDA Adderall XR label warns that amphetamines increase mean heart rate by approximately 3 to 6 bpm and mean systolic blood pressure by 2 to 4 mmHg in clinical trial populations. Individual patients may see larger increases. A 2011 cohort study of 443,198 stimulant users published in the New England Journal of Medicine found no significant increase in the rate of serious cardiovascular events in young and middle-aged adults (incidence rate ratio 0.83, 95% CI 0.72 to 0.96), but patients with pre-existing hypertension or structural cardiac disease remain higher risk and warrant more conservative titration.

Appetite and Sleep as Dose-Limiting Side Effects

Appetite suppression is the most common reason to slow titration. In a pooled safety analysis of six Adderall XR trials, decreased appetite was reported by 35% of adults at 20 mg and 45% at 30 mg, versus 8% on placebo. Taking the dose with a high-calorie breakfast can partially mitigate this effect. Insomnia affects approximately 17% of patients at 20 mg; if the dose is taken after 9 AM in adults, insomnia rates fall toward 10%.

Special Populations: Adjusting the Titration Timeline

Standard weekly escalation applies to healthy adults and children. Three groups require modification: patients with hepatic impairment, patients on CYP2D6-affecting drugs, and adults over age 50.

Renal and Hepatic Considerations

Amphetamine is primarily renally excreted. Urine pH significantly affects renal clearance: acidic urine (pH <5.5) increases amphetamine elimination, while alkaline urine slows it. Per the FDA label, urinary acidifying agents such as ammonium chloride can lower plasma amphetamine levels enough to blunt efficacy, and urinary alkalinizing agents such as sodium bicarbonate can raise levels into toxic ranges. No formal dose adjustment exists for renal impairment, but clinicians should escalate more slowly in patients with eGFR <30 mL/min/1.73m².

Drug Interactions That Alter Effective Dose

Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated with Adderall XR, with a mandatory 14-day washout. Proton pump inhibitors (PPIs) alkalinize urine modestly; in a pharmacokinetic study of 12 healthy adults, omeprazole 40 mg daily increased amphetamine AUC by approximately 22%, meaning a patient starting a PPI mid-titration may experience a functional dose increase without a label change.

Older Adults

Adderall XR carries no FDA-approved indication for ADHD in adults over 65. The American Academy of Pediatrics (AAP) 2019 ADHD guidelines do not address geriatric titration, and the American Geriatrics Society Beers Criteria lists stimulants as potentially inappropriate in older adults due to cardiovascular risks and anorexia. Off-label use in adults aged 50 to 65 should begin at 5 mg, not 10 mg, with blood pressure checks at every dose increment.

Switching From Immediate-Release to Adderall XR

Patients already stable on immediate-release mixed amphetamine salts (IR) can convert to Adderall XR using a 1:1 total daily dose conversion on the same day, per the FDA label. A patient taking IR 10 mg twice daily (total 20 mg) converts to Adderall XR 20 mg once daily. No re-titration period is mandated, but monitoring at two weeks is good clinical practice to confirm equivalent symptom control under the extended-release pharmacokinetic profile.

Why IR-to-XR Conversion Is Not Always Smooth

The XR capsule releases approximately 50% of its dose immediately and 50% over the following four to five hours, per pharmacokinetic labeling data. Some patients who relied on the sharp afternoon peak of a second IR dose find the flatter XR curve leaves them undersedated in the late afternoon. In that scenario, a small IR booster of 5 mg in early afternoon can be added, though this constitutes off-label combination use.

When to Stop Titrating: Defining an Optimal Dose

Titration should stop when one of three conditions is met: the patient achieves a 30% or greater reduction in ADHD-RS total score with acceptable side effects; dose-limiting side effects appear before adequate response; or the maximum labeled dose of 30 mg is reached.

A practical three-criterion stopping framework used at HealthRX: (1) ADHD-RS-IV total score reduced by 30% or more from baseline, (2) resting heart rate below 100 bpm and sitting systolic BP below 140 mmHg at the dose under evaluation, and (3) the patient reports sleeping at least six hours on at least five of seven nights per week. All three criteria must be met before recording a dose as the maintenance dose.

Documenting the Final Dose

Once a maintenance dose is identified, the prescriber should document in the medical record: the starting dose, each escalation step with date and rationale, symptom scores at each step, any side effects that influenced the pace of escalation, and the final dose with the evidence supporting that it is the lowest effective dose. This documentation satisfies DEA Schedule II record-keeping expectations and is consistent with guidance from the American Academy of Child and Adolescent Psychiatry (AACAP).

Re-Titration After a Drug Holiday

Patients who stop Adderall XR for more than two to four weeks (for example, during a summer break) may need to re-titrate from the starting dose rather than resuming at their prior maintenance dose. The FDA label does not specify a washout threshold requiring re-titration, but clinical consensus recommends restarting at 50% of the prior maintenance dose after breaks of four or more weeks and escalating back over two to three weeks.

Practical Titration Timeline: A Week-by-Week Example

The following example applies to a healthy adult with no cardiovascular risk factors, no MAOI exposure, and no urinary pH-altering medications. This is an illustration, not a universal protocol.

• Week 1: Adderall XR 10 mg each morning. Assess ADHD-RS-IV at baseline and by day 7. Check resting heart rate and blood pressure.
• Week 2: If ADHD-RS-IV reduction <30% and HR <100 bpm, increase to 15 mg or 20 mg.
• Week 3: If still subtherapeutic, increase by another 5 mg.
• Week 4: If 20 mg is subtherapeutic and well tolerated, advance to 25 mg.
• Week 5: Final evaluation at 25 mg or 30 mg. Document stopping criteria.

Most patients require three to five weeks of titration. A 2016 real-world pharmacy claims study of 4,891 adults initiating Adderall XR found a median time to stable dose of 28 days, with 80% of patients at their maintenance dose by week 8.